After Amazon and OpenAI, Synopsys (SNPS.US) also "looks to the East": plans to explore cooperation with Chinese AI laboratories on chip design technology
Global chip design software development leader Synopsys (SNPS.US) plans to explore cooperation with Chinese AI laboratories to improve the chip design process.
According to Zhihu Finance APP, Synopsys (SNPS.US), the global leader in chip design software development, plans to explore cooperation with Chinese AI labs to improve chip design processes. This move comes shortly after Synopsys signed multi-year agreements involving chip design technology with Amazon (AMZN.US) and OpenAI.
It is reported that Ravi Subramanian, Chief Product Officer of Synopsys, said the company is exploring partnerships with Chinese AI labs to develop similar tools for the Chinese market. As the demand for model training and deployment continues to grow, new AI-driven chip design tools are essential to keep up with this trend.
"We have a set of U.S. government regulations that we must comply with, and we will adhere to these regulations in any business expansion," Subramanian said. "We believe that China has its own growth momentum."
The agreement between Synopsys and OpenAI involves the development of GPT-Synopsys, an optimized dedicated model that utilizes Synopsys EDA tools to execute semiconductor design workflows.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million
Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
Crypto prices
More
